Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02964728
Other study ID # BMS-1
Secondary ID
Status Completed
Phase Phase 2
First received November 12, 2016
Last updated December 5, 2016
Start date November 2015
Est. completion date May 2016

Study information

Verified date December 2016
Source Presidio Ospedaliero Garibaldi-Centro
Contact n/a
Is FDA regulated No
Health authority Italy: The Italian Medicines Agency
Study type Interventional

Clinical Trial Summary

The effect of botulinum neurotoxin type A intradermal injection in will be evaluated in 4 patients with clinical diagnosis of burning mouth syndrome involving the anterior two-thirds of the tongue and the lower lip for at least 6 months, refractory to common pharmacological treatments. Pain severity will be measured by the visual analog scale (VAS) indicating average week pain before injection. Each patient will be injected with a total dose of 16 units (dilution: 2 ml saline) of incobotulinumA: 4 units into each side of the lower lip and 4 units into each antero-lateral side of the tongue. In order to determine if a placebo effect may be involved, we will inject 2 additional patients with saline solution using the same volumes and the same injection sites. Patients will be evaluated at 48 hours and then at 4, 8, 12, 16 and 20 weeks after the treatment. Patients treated with placebo will be treated after 4 weeks with incobotulinumA with the same dose reported above.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date May 2016
Est. primary completion date May 2016
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- burning mouth syndrome

Exclusion Criteria:

- any other mouth disorder

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Botulinum Neurotoxin Type A
topical injection
Other:
Normal saline
topical injection

Locations

Country Name City State
n/a

Sponsors (4)

Lead Sponsor Collaborator
Presidio Ospedaliero Garibaldi-Centro Carlo Besta Neurological Institute, University of Catania, University of Padova

References & Publications (3)

Lauria G, Majorana A, Borgna M, Lombardi R, Penza P, Padovani A, Sapelli P. Trigeminal small-fiber sensory neuropathy causes burning mouth syndrome. Pain. 2005 Jun;115(3):332-7. — View Citation

Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008 Sep;64(3):274-83. doi: 10.1002/ana.21427. Erratum in: Ann Neurol. 2009 Mar;65(3):359. — View Citation

Restivo DA, Tinazzi M, Patti F, Palmeri A, Maimone D. Botulinum toxin treatment of painful tonic spasms in multiple sclerosis. Neurology. 2003 Sep 9;61(5):719-20. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 0-100 mm Visual Analog Scale (VAS) improvement 1 month Yes
See also
  Status Clinical Trial Phase
Completed NCT04475614 - Therapeutic Options for Treatment of Burning Mouth Syndrome N/A
Completed NCT00374673 - Efficacy of Transcranial Magnetic Stimulation (TMS) in Chronic Idiopathic Pain Disorders Phase 3
Completed NCT04535973 - Hormonal Status and Quality of Life in Female Postmenopausal Patients With Burning Mouth Syndrome
Recruiting NCT06040190 - Effect of Treatments on Pain and Quality of Life in Individual With Burning Mouth Syndrome Phase 4
Not yet recruiting NCT05059418 - Burning Mouth Syndrome - New Diagnostic Criteria and Treatment N/A
Recruiting NCT01867151 - Effect of Gluten Free Diet in Patients With Burning Mouth Syndrome N/A
Completed NCT05872789 - Impact of Diazepam 1% Oral Gel Efficacy in Burning Mouth Syndrome N/A
Completed NCT05871580 - Effect to the Photobiomodulation in the Burning Mouth Syndrome N/A
Recruiting NCT05309070 - The Efficacy of N-acetyl-cysteine in the Treatment of Burning Mouth Syndrome N/A
Completed NCT05399238 - Thermography and Burning Mouth Syndrome
Completed NCT02580734 - Efficacy of Melatonin in Burning Mouth Syndrome (BMS) N/A
Completed NCT02382029 - Acupuncture Versus Clonazepam in Burning Mouth Syndrome Phase 0
Recruiting NCT05819697 - Reducing Patient Memory Recall in the Burning Mouth Patient Population
Completed NCT02757612 - Study Evaluating the Laser Diode Effect Burning Mouth Syndrome N/A
Completed NCT00862576 - A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome N/A
Not yet recruiting NCT04189367 - Treatment of Burning Mouth Syndrome With Integration of Traditional Chinese Medicine and Western Medicine Phase 3
Completed NCT00001524 - Thalidomide to Treat Oral Lesions in HIV-Infected Patients Phase 2
Recruiting NCT04481841 - Head Yuanshi Dian Therapy in Burning Mouth Syndrome Early Phase 1
Completed NCT02686359 - Opiorphin Levels in Fluids of Burning Mouth Syndrome Patients (OPIODYN) N/A
Completed NCT05309681 - Salivary Melatonin Levels and Sleep Quality in Patients With Burning Mouth Syndrome